Database Query Results : Atorvastatin, ,

ATV, Atorvastatin: Click to Expand ⟱
Features: Statin
Atorvastatin is a statin, i.e., an inhibitor of HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway. Clinically it is prescribed to lower LDL cholesterol and cardiovascular risk.

Atorvastatin — a synthetic small-molecule statin that competitively inhibits HMG-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate (MVA) pathway. It is a clinically approved oral lipid-lowering drug (LDL-C reduction; ASCVD risk reduction) with extensive hepatic first-pass handling and pleiotropic vascular/anti-inflammatory effects. Classification: small-molecule drug; HMG-CoA reductase inhibitor (statin). Standard abbreviation(s): ATV; (brand: Lipitor). In oncology research, its main leverage is MVA-pathway suppression leading to reduced isoprenoid supply (FPP/GGPP) and impaired prenylation-dependent signaling (Ras/Rho family), with context-dependent chemosensitization/radiosensitization reported in preclinical and limited clinical settings.

Primary mechanisms (ranked):

  1. HMGCR inhibition → ↓ mevalonate flux → ↓ FPP/GGPP isoprenoids → impaired protein prenylation (Ras/Rho/Rac signaling dependence)
  2. ↓ prenylation/↓ lipid-raft cholesterol support → attenuation of growth, survival, EMT/migration programs (context-dependent)
  3. Compensatory sterol-feedback rewiring (SREBP2-driven upregulation of MVA genes; “restore-the-pathway” resistance axis)
  4. Immuno-inflammatory modulation (often ↓ NF-κB–linked cytokine programs; tumor-context dependent)
  5. Cell-stress outputs (apoptosis/autophagy modulation; mitochondrial stress/ROS changes in some models)
  6. Therapy interaction phenotypes (chemosensitization and radiosensitization in selected contexts; not universal)

Bioavailability / PK relevance: Oral dosing with high hepatic extraction; exposure is strongly interaction-sensitive because atorvastatin is a CYP3A4 substrate and also uses hepatic transport (e.g., OATP1B1/1B3). Clinically meaningful systemic levels are achievable, but many anticancer in-vitro concentrations may exceed typical free plasma exposures; tumor delivery and intracellular “on-pathway” inhibition are therefore context- and dosing-dependent.

In-vitro vs systemic exposure relevance: Antiproliferative/EMT and apoptosis effects in cell culture are frequently reported at micromolar concentrations, which may be higher than unbound systemic exposures in humans; the most translatable mechanism is on-target MVA suppression with downstream prenylation stress, especially where tumors are MVA-addicted or combined with agents that block feedback/compensation.

Clinical evidence status: Approved drug for dyslipidemia/ASCVD prevention. In cancer: extensive preclinical literature plus observational associations; limited interventional oncology studies exist (including biomarker-focused trials and combination/adjunct concepts). Overall status: repurposing candidate with context-dependent signals; not an established anticancer therapy.

Across preclinical and observational contexts, atorvastatin tends to:
-DOWNREGULATE proliferative and survival signaling (via impaired prenylation)
-REDUCE inflammatory signaling (NF-κB–linked effects)
-MODULATE immune and stromal interactions
-SENSITIZE some tumors to chemotherapy or radiation (context-dependent)
-Epidemiologic studies suggest statin use is associated with reduced incidence or improved outcomes in some cancers (e.g., colorectal, prostate, breast).

Atorvastatin — cancer-relevant mechanistic axes (ranked)

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Mevalonate pathway suppression HMGCR ↓ → MVA flux ↓ HMGCR ↓ (hepatic target) P/R Depletes sterols + isoprenoids upstream On-target mechanism; anticancer relevance rises in MVA-addicted tumors and when combined with strategies that prevent compensation.
2 Protein prenylation stress Ras/Rho/Rac prenylation ↓ → signaling output ↓ Variable; typically tolerated at clinical doses R Disrupts membrane localization of key GTPases Central downstream effector of anticancer activity; impacts proliferation, migration, cytoskeletal dynamics, and survival programs.
3 SREBP2 feedback and “restore-the-pathway” resistance SREBP2 ↑ (often) → HMGCR/MVA genes ↑ (adaptive) SREBP2 ↑ (homeostatic lipid control) G Adaptive rewiring that can blunt efficacy Common translational constraint: tumors may upregulate MVA pathway, increase uptake, or rewire metabolism to bypass blockade.
4 Growth and survival signaling PI3K–AKT ↔/↓, MAPK ↔/↓ (model-dependent) Endothelial survival ↔/↑ (context-dependent) R/G Downshifts pro-survival signaling tone Often secondary to prenylation/lipid-raft disruption; direction depends on oncogenic wiring and dose.
5 Migration, invasion, EMT EMT ↓, motility ↓ (often) Wound/repair migration ↔ G Anti-migratory / anti-invasive phenotype Mechanistically linked to Rho-family prenylation and cytoskeletal/ECM programs; may be clinically relevant in select settings.
6 Inflammation and NF-κB-linked cytokine programs IL-6/IL-8/TNF-α ↓ (often) Vascular inflammation ↓ R/G Anti-inflammatory immunometabolic shift Pleiotropic statin effects; may affect tumor microenvironment and therapy tolerance, but tumor-immune direction can be context-dependent.
7 ROS and mitochondrial stress ROS ↑ (sometimes; dose-dependent) Oxidative injury ↔/↓ in vascular contexts P/R Stress signaling that can promote apoptosis or sensitize to therapy Reported in subsets of models; not universally primary. Separate “cancer cell ROS ↑” from “vascular protective” pleiotropy.
8 Cell death programs Apoptosis ↑; autophagy ↔/↑ (model-dependent) Generally cytoprotective at therapeutic dosing R/G Stress-induced cell fate shift Often downstream of prenylation deficit + metabolic stress; strong effects often require higher concentrations or combinations.
9 Drug transport and resistance P-gp ↓ (reported); efflux ↔/↓ (context-dependent) Transporter effects ↔ R/G Potential bioenhancement / chemosensitization May contribute to combination effects, but clinical relevance is uncertain and interaction risk must be managed.
10 Radiosensitization and chemosensitization RadioS ↑; ChemoSen ↑ (subset) Normal tissue injury ↔/↓ (some contexts) G Adjunct therapy leverage (context-dependent) Signals exist in preclinical and limited clinical/biomarker work; not a class-wide guarantee and may depend on tumor MVA reliance.
11 Clinical Translation Constraint Free exposure may be below many in-vitro “kill” concentrations; adaptive SREBP2 feedback; tumor heterogeneity Myopathy/rhabdomyolysis risk ↑ with interacting drugs; hepatic enzyme elevations; pregnancy contraindication — Defines practical therapeutic window Major constraints: CYP3A4/transport interactions (e.g., strong inhibitors; grapefruit), muscle toxicity risk, and uncertain tumor delivery/on-target engagement at tolerated doses.

TSF legend: P: 0–30 min   R: 30 min–3 hr   G: >3 hr
Scientific Papers found: Click to Expand⟱
4988- ATV,  Dipy,    Repurposing of the Cardiovascular Drug Statin for the Treatment of Cancers: Efficacy of Statin–Dipyridamole Combination Treatment in Melanoma Cell Lines
- in-vivo, Melanoma, NA
HMGCR↓, SREBP2↑, SREBP2↓, AntiAg↑,
5454- ATV,    Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility
- Review, BC, NA
HMG-CoA↓, HMGCR↓, TumCP↓, RadioS↑, CD44↓, P53↑,
5453- ATV,    Epidemiologic Analysis Along the Mevalonate Pathway Reveals Improved Cancer Survival in Patients Who Receive Statins Alone and in Combination With Bisphosphonates
- Trial, Var, NA
OS↑, eff↑, other↝,
5452- ATV,    Mevalonate pathway in pancreatic ductal adenocarcinoma: mechanisms driving metabolic and cellular plasticity
- Review, Var, NA
ChemoSen↑, HMG-CoA↓, EMT↓, Ferroptosis↑, Hif1a↓,
5451- ATV,    In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells
- in-vitro, BC, MDA-MB-231 - in-vitro, GBM, U87MG - in-vitro, GBM, A172
TumAuto↑, CSCs↓, HMG-CoA↓, TumCP↓, tumCV↓, TumCCA↑, TumCG↓, HMGCR↓,
5450- ATV,    The Mevalonate Pathway in the Radiation Response of Cancer
- vitro+vivo, Var, NA
eff↑, RadioS↑,
5449- ATV,    Pleiotropic effects of statins: A focus on cancer
- NA, Var, NA
lipid-P↓, TumCG↓, Apoptosis↑, ChemoSen↑, RAS↓, HMG-CoA↓, HMGCR↓, LDL↓, toxicity↓, Risk↓, P21↑, HDAC↓, Bcl-2↓, BAX↑, BIM↑, Casp↑, cl‑PARP↑, MMP↓, ROS↑, angioG↓, TumMeta↓, PTEN↑, eff↑, OS↑, Remission↑,
5448- ATV,    Beyond cardiovascular health: The pharmacotherapeutic potential of statins in oncology
- Review, Var, NA
Apoptosis↑, TumAuto↑, TumCCA↑, BioAv↓, eff↑, HMGCR↓, LDL↓, cardioP↑, AntiTum↑, ChemoSen↑, RadioS↑, toxicity↓,
5447- ATV,    The Mevalonate Pathway, a Metabolic Target in Cancer Therapy
- Review, Var, NA
Risk↓, Dose↑, ChemoSen↑, chemoP↑, HMG-CoA↓, EMT↓, CSCs↓, HH↝, YAP/TEAD↝,
5446- ATV,    Targeting the Mevalonate Pathway in Cancer
- Review, Var, NA
EMT↓, HMG-CoA↓,
5445- ATV,    Atorvastatin
- NA, Nor, NA
*cardioP↑, *LDL↓, HMG-CoA↓, Half-Life↝, BioAv↓, Dose↝,
4986- ATV,  Dipy,    The combination of statins and dipyridamole is effective preclinically in AML, MM, and breast cancer
- Review, Var, NA
HMG-CoA↓, AntiAg↑, eff↑, Apoptosis↑, selectivity↑, *toxicity↓, TumCG↓, PDE4↓, other↑,
4985- ATV,  Dipy,    Repurposing of the Cardiovascular Drug Statin for the Treatment of Cancers: Efficacy of Statin-Dipyridamole Combination Treatment in Melanoma Cell Lines
- in-vivo, Melanoma, SK-MEL-28 - in-vitro, BC, MDA-MB-435
HMG-CoA↓, SREBP2↓, eff↑, HMGCR⇅, ChemoSen↑,
4982- ATV,    Inhibiting the mevalonate pathway with atorvastatin alters gut microbiota and has potential as an anti-cancer treatment for ovarian cancer
- in-vivo, Ovarian, NA
HMG-CoA↓, GutMicro↑,
4981- ATV,    Crosstalk between Statins and Cancer Prevention and Therapy: An Update
Apoptosis↑, selectivity↑, eff↑, HMG-CoA↓, *cardioP↑, OS↑, IL1β↓, IL6↓, IL8↓, TNF-α↓, TumAuto↑, Histones↝, ac‑H3↑, ac‑H4↑, HDAC↓,
4980- ATV,    A review of effects of atorvastatin in cancer therapy
- Review, Var, NA
HMG-CoA↓, TumCP↓, TumCMig↓,
4979- ATV,  Rad,    Short‐Term Statin Treatment Reduces, and Long‐Term Statin Treatment Abolishes, Chronic Vascular Injury by Radiation Therapy
- in-vivo, Nor, NA
radioP↑, radioP↑,
4978- ATV,  Rad,    Atorvastatin Sensitizes Breast and Lung Cancer Cells to Ionizing Radiation
- in-vitro, BC, A549
Apoptosis↑, RadioS↑, TumCP↓, ROS↑,
4987- Dipy,  ATV,    Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combination
- in-vivo, Nor, NA
*cardioP↑, *Akt↑, *eNOS↑,
4984- Dipy,  ATV,    Immediate Utility of Two Approved Agents to Target Both the Metabolic Mevalonate Pathway and Its Restorative Feedback Loop
- in-vitro, AML, NA
eff↑, Apoptosis↑, selectivity↑, TumCG↓, HMG-CoA↓, HMGCR↑,
4983- Dipy,  ATV,    Targeting tumor cell metabolism via the mevalonate pathway: Two hits are better than one
- Review, Var, NA
HMG-CoA↓, AntiTum↓, eff↑,
1802- NarG,  ATV,    Bioenhancing effects of naringin on atorvastatin
- in-vivo, Nor, NA
BioEnh↑, LDL↓, P450↓, P-gp↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 22

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Ferroptosis↑, 1,   lipid-P↓, 1,   ROS↑, 2,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 1,  

Core Metabolism/Glycolysis ⓘ

Histones↝, 1,   HMG-CoA↓, 14,   LDL↓, 3,   SREBP2↓, 2,   SREBP2↑, 1,  

Cell Death ⓘ

Apoptosis↑, 6,   BAX↑, 1,   Bcl-2↓, 1,   BIM↑, 1,   Casp↑, 1,   Ferroptosis↑, 1,   YAP/TEAD↝, 1,  

Transcription & Epigenetics ⓘ

ac‑H3↑, 1,   ac‑H4↑, 1,   other↑, 1,   other↝, 1,   tumCV↓, 1,  

Autophagy & Lysosomes ⓘ

TumAuto↑, 3,  

DNA Damage & Repair ⓘ

P53↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence ⓘ

P21↑, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

CD44↓, 1,   CSCs↓, 2,   EMT↓, 3,   HDAC↓, 2,   HH↝, 1,   HMGCR↓, 5,   HMGCR↑, 1,   HMGCR⇅, 1,   PTEN↑, 1,   RAS↓, 1,   TumCG↓, 4,  

Migration ⓘ

AntiAg↑, 2,   TumCMig↓, 1,   TumCP↓, 4,   TumMeta↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   Hif1a↓, 1,  

Barriers & Transport ⓘ

P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

IL1β↓, 1,   IL6↓, 1,   IL8↓, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioEnh↑, 1,   ChemoSen↑, 5,   Dose↑, 1,   Dose↝, 1,   eff↑, 9,   Half-Life↝, 1,   P450↓, 1,   RadioS↑, 4,   selectivity↑, 3,  

Clinical Biomarkers ⓘ

GutMicro↑, 1,   IL6↓, 1,  

Functional Outcomes ⓘ

AntiTum↓, 1,   AntiTum↑, 1,   cardioP↑, 1,   chemoP↑, 1,   OS↑, 3,   PDE4↓, 1,   radioP↑, 2,   Remission↑, 1,   Risk↓, 2,   toxicity↓, 2,  
Total Targets: 70

Pathway results for Effect on Normal Cells:


Core Metabolism/Glycolysis ⓘ

LDL↓, 1,  

Cell Death ⓘ

Akt↑, 1,  

Angiogenesis & Vasculature ⓘ

eNOS↑, 1,  

Functional Outcomes ⓘ

cardioP↑, 3,   toxicity↓, 1,  
Total Targets: 5

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:2  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page